<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33382412</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2180</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Carcinogenesis</Title>
          <ISOAbbreviation>Carcinogenesis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.</ArticleTitle>
        <Pagination>
          <StartPage>517</StartPage>
          <EndPage>527</EndPage>
          <MedlinePgn>517-527</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/carcin/bgaa144</ELocationID>
        <Abstract>
          <AbstractText>The neoplastic Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) depend on chronic activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling pathways to maintain survival and proliferation. Accumulating reports highlight the importance of the inactivation or reduced expression of negative JAK/STAT regulators such as the protein-tyrosine phosphatase 1B (PTP1B/PTPN1) in this process. Various PTPN1 mRNA variants as well as truncated PTP1B proteins were identified in cHL cell lines and primary cHL tumour samples. These PTPN1 mRNA variants lack either one or several exon sequences and therefore render these PTP1B variants catalytically inactive. Here, we show that one of these mutants, PTP1B∆2-4, is not only a catalytically inactive variant, but also augmented the IL-4-induced JAK/STAT activity similar to the recently reported PTP1B∆6 splice variant. Moreover, while PTP1B∆6 diminished the activity and protein levels of PTP1BWT, PTP1BWT remained unaffected by PTP1B∆2-4, arguing for different molecular mechanisms of JAK/STAT modulation by PTP1B∆6 and PTP1B∆2-4. Collectively, these data indicate that PTPN1 variants missing one or more exon sequences originated either from alternative splicing or from gene mutation, create PTP1B gain-of-function variants with oncogenic potential by augmenting JAK/STAT signalling in cHL.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zahn</LastName>
            <ForeName>Malena</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, Ulm University, Albert-Einstein-Allee, Ulm, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaluszniak</LastName>
            <ForeName>Bianca</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, Ulm University, Albert-Einstein-Allee, Ulm, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Möller</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, Ulm University, Albert-Einstein-Allee, Ulm, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marienfeld</LastName>
            <ForeName>Ralf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, Ulm University, Albert-Einstein-Allee, Ulm, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Carcinogenesis</MedlineTA>
        <NlmUniqueID>8008055</NlmUniqueID>
        <ISSNLinking>0143-3334</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="C516607">PTPN1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054562" MajorTopicYN="N">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>12</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33382412</ArticleId>
        <ArticleId IdType="pmc">PMC8086765</ArticleId>
        <ArticleId IdType="doi">10.1093/carcin/bgaa144</ArticleId>
        <ArticleId IdType="pii">6056480</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>

Bräuninger, A., et al.  (2006) Molecular biology of Hodgkin’s and Reed/Sternberg cells in Hodgkin’s lymphoma. Int. J. Cancer, 118, 1853–1861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16385563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Ansell, S.M. (2016) Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 91, 434–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27001163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Küppers, R., et al.  (2012) Hodgkin lymphoma. J. Clin. Invest., 122, 3439–3447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3534167</ArticleId>
            <ArticleId IdType="pubmed">23023715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Vockerodt, M., et al.  (2015) The Epstein-Barr virus and the pathogenesis of lymphoma. J. Pathol., 235, 312–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25294567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Scott, D.W., et al.  (2014) The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer, 14, 517–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25008267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Murray, P.J. (2007) The JAK-STAT signaling pathway: input and output integration. J. Immunol., 178, 2623–2629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17312100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Thomas, S.J., et al.  (2015) The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer, 113, 365–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522639</ArticleId>
            <ArticleId IdType="pubmed">26151455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Yip, S.C., et al.  (2010) PTP1B: a double agent in metabolism and oncogenesis. Trends Biochem. Sci., 35, 442–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917533</ArticleId>
            <ArticleId IdType="pubmed">20381358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Tiacci, E., et al.  (2018) Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood, 131, 2454–2465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6634958</ArticleId>
            <ArticleId IdType="pubmed">29650799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Blanquart, C., et al.  (2009) Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem. Biophys. Res. Commun., 387, 748–753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19635455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Hoekstra, E., et al.  (2016). Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. Oncotarget, 7(16), 21922–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5008334</ArticleId>
            <ArticleId IdType="pubmed">26942883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gunawardana, J., et al.  (2014) Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat. Genet., 46, 329–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24531327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Zahn, M., et al.  (2017) A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood, 129, 1480–1490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28082443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Union for International Cancer Control. (2014) HODGKIN LYMPHOMA (ADULT) [Internet]. Medicines for treatment of the following cancers – review – EML and EMLc. 20th Expert Committee on the Selection and Use of Essential Medicines. 2014. p. 1–9.</Citation>
        </Reference>
        <Reference>
          <Citation>

Mader, A., et al.  (2007) U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet. Genome Res., 119, 204–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18253030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Palkowitsch, L., et al.  (2011) The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. J. Biol. Chem., 286, 7522–7534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3045007</ArticleId>
            <ArticleId IdType="pubmed">21199863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rao, X., et al.  (2013) An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat. Bioinforma. Biomath., 3, 71–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4280562</ArticleId>
            <ArticleId IdType="pubmed">25558171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Knecht, H., et al.  (2010) 3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1 and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short telomeres including “t-stumps”. BMC Cell Biol., 11, 99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3018409</ArticleId>
            <ArticleId IdType="pubmed">21144060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gunawardana, J., et al.  (2013) Protein tyrosine phosphatase type-1 (PTPN1) is frequently mutated in primary mediastinal B cell lymphoma and Hodgkin lymphoma No Title. Blood, 122(21), 242.</Citation>
        </Reference>
        <Reference>
          <Citation>

Skinnider, B.F., et al.  (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, 99, 618–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11781246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Skinnider, B.F., et al.  (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283–4297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12036854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Skinnider, B.F., et al.  (2001) Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, 97, 250–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11133768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Baus, D., et al.  (2006) Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int. J. Cancer, 118, 1404–1413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16206268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kube, D., et al.  (2001) STAT3 is constitutively activated in Hodgkin cell lines. Blood, 98, 762–770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11468177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Weniger, M.A., et al.  (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene, 25, 2679–2684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16532038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Delgado-Martin, C., et al.  (2017) JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia, 31, 2568–2576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5729333</ArticleId>
            <ArticleId IdType="pubmed">28484265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Heuck, F., et al.  (2004) Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J. Immunother., 27, 347–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15314543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Tan, F.H., et al.  (2014) The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr. Drug Targets, 15, 1341–1353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25410411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Chen, L., et al.  (2018) Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncol Rep., 39, 1081–1089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5802029</ArticleId>
            <ArticleId IdType="pubmed">29328487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kaewpiboon, C., et al.  (2015) Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells. Mol. Med. Rep., 11, 2315–2321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25395162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Meissl, K., et al.  (2017) The good and the bad faces of STAT1 in solid tumours. Cytokine, 89, 12–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26631912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pike, K.A., et al.  (2016) TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. Cytokine, 82, 52–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26817397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Mottok, A., et al.  (2007) Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood, 110, 3387–3390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17652621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Chikuma, S., et al.  (2017) Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci., 108, 574–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5406529</ArticleId>
            <ArticleId IdType="pubmed">28188673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kleppe, M., et al.  (2011) Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma. Haematologica, 96, 1723–1727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208694</ArticleId>
            <ArticleId IdType="pubmed">21791476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Barrett, W.C., et al.  (1999) Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry, 38, 6699–6705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10350489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lee, S.R., et al.  (1997) Reversible inactivation of protein tyrosine phosphatase IB by hydrogen peroxide generated in A431 cells stimulated with epidermal growth factor. FASEB J., 11(9), 15366–72.</Citation>
        </Reference>
        <Reference>
          <Citation>

Ravichandran, L.V., et al.  (2001) Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor. Mol. Endocrinol., 15, 1768–1780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11579209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Vainchenker, W., et al.  (2013) JAK/STAT signaling in hematological malignancies. Oncogene, 32347, 2601–1310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22869151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lessard, L., et al.  (2010) The two faces of PTP1B in cancer. Biochim. Biophys. Acta - Proteins Proteomics, 1804, 613–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19782770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Dubé, N., et al.  (2004) The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. U. S. A., 101, 1834–1839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC357013</ArticleId>
            <ArticleId IdType="pubmed">14766979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Tiganis, T. (2013) PTP1B and TCPTP–nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J., 280, 445–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22404968</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
